Dopamine is a major neurotransmitter in the brain. A dopamine
deficiency is associated with Parkinson's disease, while overactive dopaminergic
systems are associated with schizophrenia and other mental diseases. Recent
research associated with the new gene related to the Parkinson’s disease. From
this research, it is easy to design new therapies to slow neurodegeneration in
the brains of patients with Parkinson’s disease and other related disorders.
NFE2L1 is a protein that controls the expression of genes
involved in the differentiation and survival of dopamine neurons. NFE2L1 levels
are reduced in dopamine neurons in the brains of Parkinson’s disease
patients. A large-scale of the genomic
study found that a minor allele of NFE2L1 can lower Parkinson’s risk. These
observations imply that neuron death in Parkinson’s disease may result in part
from a loss of the Neuroprotective action of NFE2L1. It hypothesizes that an
increase of NFE2L1 can alleviate neuron death in rodent models of Parkinson’s
disease. The results of the study will shed light on the ability of NFE2L1 to
reduce neurotoxicity throughout the brain. By increasing NFE2L1 levels in the
brain, it will be developing the Parkinson’s diseases therapies.
It creates the new clinical application for
those compounds which increase NFE2L1 levels in the brain, either by
stimulating the protein’s expression or blocking the Protein’s destruction by
the proteasome. NFE2L1 can relieve neuron demise related with alpha-synuclein
amassing and aggregate formation- the trademark pathology of Parkinson's - in
pre-clinical models of Parkinson malady. Alpha-synuclein (also known as
α-synuclein) is a protein whose function is crucial for the healthy brain. It
is of remarkable interest to Parkinson's researchers due to the fact it is a
primary constituent of Lewy bodies, protein clumps which can be the
pathological hallmark of Parkinson's disease.
For more details visit: https://bioorganic-medicinal.chemistryconferences.org/
No comments:
Post a Comment